Page B. Pennell, M.D.
Associate Professor of Neurology
Phone: 404.778.5943
Education
Emory University, Atlanta, GA B.S. 1985 Biology
University of Florida, Gainesville, FL M.D. 1989 Medicine
University of Florida, Gainesville, FL M.D. 1989 Medicine
Positions and Employment
1989-90 Internal Medicine Internship; University of Florida Health Sciences Center, Gainesville FL
1990-93 Neurology Residency; University of Michigan Medical Center, Ann Arbor MI
1993-95 Clinical Neurophysiology Fellowship; University of Michigan Medical Center, Ann Arbor MI
1995-03 Assistant Professor, Department of Neurology; Emory University School of Medicine
1997-98 Associate Director, Emory Program for Neurologic Disorders in Women
1996-present Director, Epilepsy Monitoring Unit
2003-present Associate Professor, Department of Neurology: Emory University School of Medicine
Other Experience and Professional Memberships
1990-present American Academy of Neurology
1993- present American Epilepsy Society
1995- present American Clinical Neurophysiology Society
1995-99 American Medical Association
1997-99 AMA Women Physicians Congress
1997-present Southern Epilepsy and EEG Society
1997-04 Professional Advisory Board, Epilepsy Foundation of America, Georgia Chapter
1999-present Women and Epilepsy Initiative Speakers Bureau, Epilepsy Foundation of America
1998-03 Chair, Liaison/Communications, Women‚s Issues in Neurology Section, American Academy of Neurology
2003-present Secretary, Women‚s Issues in Neurology Section, American Academy of Neurology
1999-present Vice-Chair, Issues of Concern for Women with Epilepsy, American Epilepsy Society
2001-present Member, Annual Course Committee, American Epilepsy Society
1990-93 Neurology Residency; University of Michigan Medical Center, Ann Arbor MI
1993-95 Clinical Neurophysiology Fellowship; University of Michigan Medical Center, Ann Arbor MI
1995-03 Assistant Professor, Department of Neurology; Emory University School of Medicine
1997-98 Associate Director, Emory Program for Neurologic Disorders in Women
1996-present Director, Epilepsy Monitoring Unit
2003-present Associate Professor, Department of Neurology: Emory University School of Medicine
Other Experience and Professional Memberships
1990-present American Academy of Neurology
1993- present American Epilepsy Society
1995- present American Clinical Neurophysiology Society
1995-99 American Medical Association
1997-99 AMA Women Physicians Congress
1997-present Southern Epilepsy and EEG Society
1997-04 Professional Advisory Board, Epilepsy Foundation of America, Georgia Chapter
1999-present Women and Epilepsy Initiative Speakers Bureau, Epilepsy Foundation of America
1998-03 Chair, Liaison/Communications, Women‚s Issues in Neurology Section, American Academy of Neurology
2003-present Secretary, Women‚s Issues in Neurology Section, American Academy of Neurology
1999-present Vice-Chair, Issues of Concern for Women with Epilepsy, American Epilepsy Society
2001-present Member, Annual Course Committee, American Epilepsy Society
Honors and Awards
1985 Magna cum laude, Emory University
1988 Whitehead Medical Scholarship
1989 Roger G. Schnell Award for Outstanding Skills in Neurology
1990 Diplomate, National Board of Medical Examiners
1994 Diplomate, American Board of Neurology and Psychiatry
1996 Diplomate, American Board of Clinical Neurophysiology
1999 Diplomate, Subspecialty Certification in Clinical Neurophysiology, American Board of Neurology and Psychiatry
1988 Whitehead Medical Scholarship
1989 Roger G. Schnell Award for Outstanding Skills in Neurology
1990 Diplomate, National Board of Medical Examiners
1994 Diplomate, American Board of Neurology and Psychiatry
1996 Diplomate, American Board of Clinical Neurophysiology
1999 Diplomate, Subspecialty Certification in Clinical Neurophysiology, American Board of Neurology and Psychiatry
Grant Support
Active Support, Federall Funded:
Active Support, Federall Funded:
1P50 MH68036-01 NIH Z Stowe (Program PI) 10/01/02-09/30/07
Specialized Center of Research in Women and Gender Issues
Medications in Pregnancy: Defining Exposure
The central theme of this Specialized Center of Research in Women and Gender Factors is pharmacokinetic and pharmacodynamic (PK/PD) modeling of anti-epileptic drugs and psychotropic medications during pregnancy and lactation using both human and rodent paradigms: defining fetal/neonatal exposure and influence on obstetrical outcome.
Project 1: Course and Predictors of Epilepsy in Pregnancy and Postpartum
This project will study pharmacokinetic, pharmacodynamic, and pharmacogenetic (PK/PD/PG) modeling of anti-epileptic drugs during pregnancy and lactation in women with epilepsy.
Role: Project 1 Principal Investigator
P50 NS16308 NIH I Leppik (PI, U of Minnesota) 10/01/02-9/30/07
Epilepsy Clinical Research Program Grant at University of Minnesota
The major goal of this program project is to increase knowledge of the pharmacokinetic, pharmacodynamic, and pharmacoepidemiology of AEDs in the elderly. The project also includes investigation of genetic and racial factors. Projects 1 and 3 will enroll patients from 3 varied clinical sites (MINCEP, University of Miami, and Emory University).
Project 1: Effects of Age, Gender, and Race on the Metabolism of Antiepileptic Drugs
Role: Co-Investigator, Emory site Principal Investigator
Project 3. Population Pharmacokinetics of the Newer Antiepileptic Drugs in Elderly Epilepsy Patients
Role: Co-Investigator, Emory site Principal Investigator
RO1NS38455-02 NIH K Meador (PI, Georgetown University) 11/01/01-10/31/05
Neurodevelopmental Effects of Antiepileptic Drugs
This multicenter study is a comparison of the neurodevelopmental outcome of children exposed in utero to carbamazepine, phenytoin, valproate, or lamotrigine.
Role: Co-investigator, Emory site Principal Investigator
RO1 NS 39466 NIH A. Herzog (PI, Beth Israel/Harvard) 9/01/02-8/31/03
Progesterone Therapy for Women with Epilepsy
This is a four-center randomized, placebo-controlled trial evaluating the efficacy and safety of adjunctive progesterone therapy in women with medically refractory epilepsy.
Role: Co-investigator, Emory site Principal Investigator
RO1 NS38473-02 NIH Harden (PI, Cornell) 10/01/02-9/30/03
Hormone Replacement in Menopausal Women with Epilepsy
This study is a prospective, randomized, double-blind, placebo-controlled, 5 center trial evaluating the effects of hormone replacement therapy on seizure frequency and severity in menopausal women with epilepsy.
Role: Co-investigator, Emory site Principal Investigator
Active Support, Private Funding:
Sponsor: GlaxoSmithKline PB Pennell (PI) 8/03-8/05
The Excretion of Lamotrigine into Human Breast Milk: Determining Nursing Infant Daily Dose
This is a three-center study of the pharmacokinetics and pharmacodynamics of lamotrigine in breast feeding mother-child pairs, and in newborns exposed to lamotrigine in utero (neonatal clearance).
Role: Study Principal Investigator
Sponsor: Pfizer PB Pennell (PI) 9/01/98-09/01/03
Cyclic Reproductive Hormones and AED Levels in Women with Catamenial Epilepsy
This is an observational study of the relationships between seizure frequency and sex steroid hormone levels and antiepileptic drug levels in women with catamenial epilepsy.
Role: Principal Investigator
Sponsor: UCB Pharma PB Pennell (PI) 9/01/02-9/01/03
A Pilot Trial of the Use of Levetiracetam in the Treatment of Catamenial Epilepsy
This is an investigator-initiated, single-center, pilot trial evaluating the safety, efficacy, and tolerability of adjunctive cyclic levetiracetam in the treatment of women with medically refractory partial epilepsy with a catamenial pattern.
Role: Principal Investigator
Sponsor: GlaxoSmithKline A Herzog (Project PI, Beth Israel/Harvard) 8/01/02-8/01/03
Reproductive Endocrine Function in Men with Epilepsy
This is a three-center study examining reproductive hormone levels in men with partial epilepsy in relation to specific antiepileptic drugs.
Role: Emory Principal Investigator
Sponsor: UCB Pharma 10/01/02-10/01/04
A Multicenter, Double-blind, Placebo-controlled, Parallel Group Study of the Safety and Efficacy of Perimenstrual Pulse Dosing of LEV in the Adjunctive Treatment of Adult Female Subjects with C1 Catamenial Epilepsy, Protocol N01088.
Role: Emory Principal Investigator
Sponsor: industry K Meador (PI, Georgetown University) 1/01/03-11/01/05
Retrospective Study of In-Utero Anti-Epileptic Drug Effects on Neurodevelopment
The specific aim of this multicenter retrospective parallel group study is to determine if in utero exposure produces differential anti-epileptic drug (AED) effects on subsequent cognitive abilities and behavioral abnormalities in children.
Role: Emory Principal Investigator
Specialized Center of Research in Women and Gender Issues
Medications in Pregnancy: Defining Exposure
The central theme of this Specialized Center of Research in Women and Gender Factors is pharmacokinetic and pharmacodynamic (PK/PD) modeling of anti-epileptic drugs and psychotropic medications during pregnancy and lactation using both human and rodent paradigms: defining fetal/neonatal exposure and influence on obstetrical outcome.
Project 1: Course and Predictors of Epilepsy in Pregnancy and Postpartum
This project will study pharmacokinetic, pharmacodynamic, and pharmacogenetic (PK/PD/PG) modeling of anti-epileptic drugs during pregnancy and lactation in women with epilepsy.
Role: Project 1 Principal Investigator
P50 NS16308 NIH I Leppik (PI, U of Minnesota) 10/01/02-9/30/07
Epilepsy Clinical Research Program Grant at University of Minnesota
The major goal of this program project is to increase knowledge of the pharmacokinetic, pharmacodynamic, and pharmacoepidemiology of AEDs in the elderly. The project also includes investigation of genetic and racial factors. Projects 1 and 3 will enroll patients from 3 varied clinical sites (MINCEP, University of Miami, and Emory University).
Project 1: Effects of Age, Gender, and Race on the Metabolism of Antiepileptic Drugs
Role: Co-Investigator, Emory site Principal Investigator
Project 3. Population Pharmacokinetics of the Newer Antiepileptic Drugs in Elderly Epilepsy Patients
Role: Co-Investigator, Emory site Principal Investigator
RO1NS38455-02 NIH K Meador (PI, Georgetown University) 11/01/01-10/31/05
Neurodevelopmental Effects of Antiepileptic Drugs
This multicenter study is a comparison of the neurodevelopmental outcome of children exposed in utero to carbamazepine, phenytoin, valproate, or lamotrigine.
Role: Co-investigator, Emory site Principal Investigator
RO1 NS 39466 NIH A. Herzog (PI, Beth Israel/Harvard) 9/01/02-8/31/03
Progesterone Therapy for Women with Epilepsy
This is a four-center randomized, placebo-controlled trial evaluating the efficacy and safety of adjunctive progesterone therapy in women with medically refractory epilepsy.
Role: Co-investigator, Emory site Principal Investigator
RO1 NS38473-02 NIH Harden (PI, Cornell) 10/01/02-9/30/03
Hormone Replacement in Menopausal Women with Epilepsy
This study is a prospective, randomized, double-blind, placebo-controlled, 5 center trial evaluating the effects of hormone replacement therapy on seizure frequency and severity in menopausal women with epilepsy.
Role: Co-investigator, Emory site Principal Investigator
Active Support, Private Funding:
Sponsor: GlaxoSmithKline PB Pennell (PI) 8/03-8/05
The Excretion of Lamotrigine into Human Breast Milk: Determining Nursing Infant Daily Dose
This is a three-center study of the pharmacokinetics and pharmacodynamics of lamotrigine in breast feeding mother-child pairs, and in newborns exposed to lamotrigine in utero (neonatal clearance).
Role: Study Principal Investigator
Sponsor: Pfizer PB Pennell (PI) 9/01/98-09/01/03
Cyclic Reproductive Hormones and AED Levels in Women with Catamenial Epilepsy
This is an observational study of the relationships between seizure frequency and sex steroid hormone levels and antiepileptic drug levels in women with catamenial epilepsy.
Role: Principal Investigator
Sponsor: UCB Pharma PB Pennell (PI) 9/01/02-9/01/03
A Pilot Trial of the Use of Levetiracetam in the Treatment of Catamenial Epilepsy
This is an investigator-initiated, single-center, pilot trial evaluating the safety, efficacy, and tolerability of adjunctive cyclic levetiracetam in the treatment of women with medically refractory partial epilepsy with a catamenial pattern.
Role: Principal Investigator
Sponsor: GlaxoSmithKline A Herzog (Project PI, Beth Israel/Harvard) 8/01/02-8/01/03
Reproductive Endocrine Function in Men with Epilepsy
This is a three-center study examining reproductive hormone levels in men with partial epilepsy in relation to specific antiepileptic drugs.
Role: Emory Principal Investigator
Sponsor: UCB Pharma 10/01/02-10/01/04
A Multicenter, Double-blind, Placebo-controlled, Parallel Group Study of the Safety and Efficacy of Perimenstrual Pulse Dosing of LEV in the Adjunctive Treatment of Adult Female Subjects with C1 Catamenial Epilepsy, Protocol N01088.
Role: Emory Principal Investigator
Sponsor: industry K Meador (PI, Georgetown University) 1/01/03-11/01/05
Retrospective Study of In-Utero Anti-Epileptic Drug Effects on Neurodevelopment
The specific aim of this multicenter retrospective parallel group study is to determine if in utero exposure produces differential anti-epileptic drug (AED) effects on subsequent cognitive abilities and behavioral abnormalities in children.
Role: Emory Principal Investigator
Selected Completed Research Support
Elan Pharmaceuticals PB Pennell (Emory PI) 2/01/98-8/31/01
ZNS 501, A Multicenter, open-label safety study to evaluate the Use of 25 mg and 50 mg Zonegran in the initiation of therapy in patients with epilepsy
Novartis Pharmaceuticals PB Pennell (Emory PI) 1/15/98-8/31/01
GP 47779 (MHD), Protocol 477790103: Multicenter, double-blind, randomized, placebo-controlled, 2-arm parallel-group trial of GP 47779 (Monohydroxy derivative of oxcarbazepine), administered intravenously, to inpatients with epilepsy who are undergoing evaluation for epilepsy surgery
Novartis Pharmaceuticals PB Pennell (Emory PI) 1/15/98-8/31/01
GP 46780 (oxcarbazepine); Protocol 4768002031: Open-label, multicenter extension trial of oxcarbazepine in patients with refractory partial seizures who completed Protocol 4777901003
UCB Pharma, Inc. PB Pennell (Emory PI) 3/22/00-3/21/01
Protocol N158: „Multicenter study comparing levetiracetam to valproate monotherapy in epileptic patients
RW Johnson PRI PB Pennell (Emory PI) 1995-1998
Topiramate Monotherapy Clinical Trial in Subjects with Recently Diagnosed Partial-Onset Seizures, Protocol TOPMAT-EPMN-104
RW Johnson PRI PB Pennell (Emory PI) 1995-1998
YLT: Phase III, A Long-Term Open Label Extension Study of Topiramate
CoCensys PB Pennell (Emory PI) 1997
A Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Antiepileptic Activity of Ganaxolone in Patients Undergoing Evaluation to Determine Suitability for Surgical Treatment of Complex Partial Seizures